Will Compounded Tirzepatide Still Be Available?

Last reviewed: June 7, 2026

Last updated: June 7, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Tirzepatide, a dual GLP-1 and GIP receptor agonist, has generated significant patient interest since its approval for diabetes management. Many individuals wonder whether compounded versions of this medication will remain available as demand continues to grow. PlexusDx provides compounded tirzepatide through licensed 503A pharmacies, ensuring ongoing access without membership fees or insurance requirements.

Current Status of Compounded Tirzepatide Supply

Licensed 503A compounding pharmacies continue manufacturing tirzepatide formulations for patients nationwide. These facilities operate under strict FDA oversight and state pharmacy board regulations, ensuring quality and sterility standards equivalent to commercial pharmaceutical production. PlexusDx partners exclusively with 503A compounders—never 503B manufacturers—to deliver tirzepatide injections and oral formulations.

The compounding tirzepatide market has grown substantially as more individuals seek alternatives to brand-name medications or prefer customized dosing regimens. Supply chain stability remains strong because multiple licensed compounders produce tirzepatide, preventing single-source dependency. Current demand has not disrupted availability, and PlexusDx maintains consistent access across all 50 states.

Why Compounded Tirzepatide Remains a Viable Option

Compounding pharmacies operate within established legal frameworks that explicitly permit tirzepatide preparation when prescribed by licensed providers. The FDA recognizes compounded medications as necessary for patients requiring customized formulations, alternative delivery routes, or specific dosing schedules not available commercially. This regulatory foundation protects patient access and provides long-term stability for the compounded tirzepatide category.

Cost accessibility drives continued demand for compounded tirzepatide. PlexusDx offers compounded tirzepatide injection at a flat monthly rate at $289/mo month-to-month, or from $249/mo on the 6-month plan—your dose may need to go up, but your price won't. Patients benefit from transparent, all-inclusive pricing without surprise increases tied to dose escalation. This pricing model, combined with HSA and FSA eligibility, makes tirzepatide therapy financially sustainable for more individuals.

PlexusDx Tirzepatide Options and Delivery Methods

PlexusDx delivers two tirzepatide formulations to match individual preferences and medical needs. Compounded Tirzepatide Injection provides consistent results with straightforward weekly self-administration, at $289/mo month-to-month, or from $249/mo on the 6-month plan. For patients preferring oral delivery, PlexusDx Oral Tirzepatide is $349/mo month-to-month, or from $279/mo on the 6-month plan, offering an alternative route while maintaining therapeutic dosing principles.

Both formulations originate from licensed 503A compounding pharmacies and carry the same quality assurance standards. Patients can discuss which delivery method aligns with their lifestyle, injection comfort level, and healthcare goals during their personalized consultation. PlexusDx clinical support ensures smooth transitions and dose optimization regardless of which tirzepatide format is selected.

Genetic Testing for Personalized Tirzepatide Response

The PlexusDx Precision Peptide Genetic Test analyzes GIPR (rs1800437) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Adding genetic insights to tirzepatide therapy improves outcomes by identifying patients most likely to respond robustly to this dual-receptor approach. The Precision Peptide Genetic Test is $298 and becomes available allowing patients to personalize their weight loss strategy based on molecular biology rather than trial-and-error dosing. This data-driven approach represents precision health in practice.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Will compounded tirzepatide continue to be available in 2024 and beyond?

Yes. Compounded tirzepatide remains legally available through licensed 503A pharmacies, and PlexusDx maintains consistent national supply across all 50 states. Regulatory frameworks supporting compounded medications are stable, and multiple compounders produce tirzepatide, ensuring long-term access without supply disruptions.

How does compounded tirzepatide compare to brand-name Mounjaro in effectiveness?

Compounded tirzepatide contains the same active pharmaceutical ingredient as Mounjaro and activates identical GLP-1 and GIP receptors. Clinical outcomes depend on proper dosing, storage, and consistency—all managed by licensed 503A compounders following FDA guidelines. Individual response varies based on genetics, lifestyle, and metabolism rather than source of manufacture.

Why does PlexusDx charge a flat monthly price regardless of dose level?

PlexusDx pricing philosophy recognizes that patients require dose increases as their body adjusts to tirzepatide therapy. A flat rate ensures patients never face surprise cost jumps during treatment progression. Compounded Tirzepatide Injection is $289/mo month-to-month (or $249/mo on the 6-month plan) across all dose tiers, making long-term weight loss therapy predictable and affordable.

Are compounded tirzepatide medications FDA-approved?

Compounded tirzepatide is not FDA-approved as a compounded product, but the active ingredient itself (tirzepatide) is FDA-approved for diabetes. Licensed 503A compounding pharmacies operate under federal and state authorization to prepare tirzepatide for individual patients based on prescriptions from qualified providers.

How can the Precision Peptide Genetic Test improve my tirzepatide outcomes?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Compounded Tirzepatide
• Best Compounded Tirzepatide Providers Plexusdx
• Lifemd Tirzepatide
• Goodlife Meds Tirzepatide

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.